Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial

Axsome Doses First Patient in SUMMIT Trial

Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The initiation of the SUMMIT Phase 3 trial represents a positive development for Axsome Therapeutics, potentially expanding the commercial indications of AXS-05 into the large smoking cessation market. Successful trial results could significantly boost Axsome's revenue prospects, while failure could negatively impact its stock.

Biotechnology Pharmaceuticals

Axsome Therapeutics announced on August 31, 2026, that the first patient has been dosed in the SUMMIT Phase 3 clinical trial of AXS-05 for smoking cessation. SUMMIT is a randomized, double-blind, active- and placebo-controlled, multicenter trial that will evaluate the efficacy and safety of AXS-05 in adult smokers. Approximately 34 million adults in the U.S. smoke cigarettes, and smoking is the leading cause of preventable disease, costing over $300 billion annually. AXS-05 is an investigational oral NMDA receptor antagonist, sigma-1 agonist, and CYP2D6 inhibitor, already approved as AUVELITY for major depressive disorder and agitation associated with Alzheimer's disease. The trial will randomize smokers to receive AXS-05, bupropion, or placebo for about 12 weeks, with the primary endpoint being smoking abstinence at the end of treatment. This milestone advances Axsome's pipeline in a high unmet need area.

100 Axsome Therapeutics dosed first patient
stock
Axsome Therapeutics is the sponsor of the SUMMIT trial and the developer of AXS-05. The dosing of the first patient is a key milestone that could lead to a new indication and revenue stream, positively impacting the company's valuation.
Importance 100.0 Sentiment 20.0
govactor
The FDA is the regulatory authority that will review the trial results and any future new drug application for AXS-05 as a smoking cessation treatment. Its approval is required for market entry, but no regulatory action has been taken yet.
Importance 30.0 Sentiment 0.0
cnt
The United States is the country where the trial is being conducted and where the smoking cessation market exists. The high prevalence of smoking and associated costs highlight the potential public health and economic impact of a successful treatment.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.